Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Scientists are making major strides against "zombie cells" — senescent cells that linger in the body and drive age-related disease. Seven Mayo Clinic studies reveal why these cells are so harmful and how to target them, while a separate Cedars-Sinai discovery identifies a protein called PD-L2 that helps zombie cells hide from the immune system. Together, the findings open promising new doors for anti-aging therapies.
Scientists are closing in on one of aging's most stubborn culprits: senescent, or "zombie," cells — cells that stop dividing but refuse to die, instead releasing inflammatory signals that fuel age-related disease. Seven new studies from Mayo Clinic's Kogod Center on Aging, published in Nature journals, reveal that these cells are far more diverse than previously thought, with their characteristics varying by tissue type and the biological trigger that caused senescence. Researchers also uncovered key molecular pathways — many involving malfunctioning mitochondria — that explain why zombie cells keep stoking chronic inflammation.
A separate study from Cedars-Sinai, published in Cell Metabolism, adds another layer: a protein called PD-L2 may act as a kind of invisibility cloak, helping senescent cells evade immune clearance. Blocking PD-L2 in mice reduced zombie cell accumulation, lowered inflammation, and improved blood sugar regulation and grip strength — suggesting the immune system could be recruited to do the cleanup work.
Key Takeaways
Why it matters: These findings shift the field from simply knowing zombie cells are bad to understanding which ones cause the most damage, why they're harmful, and how to stop them — laying the groundwork for precision therapies that could meaningfully slow age-related disease.
